“Acil Servise Başvuran Kronik Digoksin Toksisitesi Olan Hastaların Klinik Özellikleri ve Sonuçları

Abstract

Keywords

• digoksin
• kronik digoksin toksisitesi
• acil servis
• yaşlı hasta

Supporting Institution

None

Project Number

196

Ethical Statement

The study protocol was approved by the Mersin University Clinical Research Ethics Committee

Thanks

None

Clinical Characteristics and Outcomes of Patients With Chronic Digoxin Toxicity Presenting to the Emergency Department

Abstract

Purpose: Digoxin is widely used to treat heart failure and atrial fibrillation but has a narrow therapeutic index, making elderly patients particularly susceptible to chronic toxicity. Because its clinical manifestations are often nonspecific, diagnosis in the emergency department (ED) may be delayed. To evaluate the demographic characteristics, clinical presentation, electrocardiographic findings, laboratory parameters, and in-hospital outcomes of patients presenting to the ED with chronic digoxin toxicity.

Methods: This retrospective cohort study included adult patients admitted to a tertiary-care ED over a five-year period who received chronic digoxin therapy and had serum digoxin levels ≥2,0 ng/mL. Patients with acute intentional overdose or incomplete medical records were excluded. Demographic characteristics, comorbidities, presenting symptoms, Electrocardiogram (ECG) findings, laboratory results, and in-hospital outcomes were analyzed.

Results: A total of 188 patients were included (mean age 73,50±12,10 years; 42,00% male). Dyspnea (35,10%), chest pain (23,40%), and nausea/vomiting (22,90%) were the most common presenting symptoms. Heart failure (76,60%) and hypertension (71,30%) were the most frequent comorbidities. Valvular heart disease was more common in patients aged ≤ 65 years (p=0,005), whereas serum sodium levels were higher in older patients (r=0,282, p<0,001). Serum digoxin levels correlated positively with potassium, urea, creatinine, creatine kinase–myocardial band (CK-MB), and troponin, and negatively with hemoglobin. Higher digoxin concentrations were associated with increased in-hospital mortality (p=0,006).

Conclusion: Chronic digoxin toxicity is an important and frequently under-recognized condition in the ED. Early recognition based on clinical, laboratory, and ECG findings may improve patient outcomes.

Keywords

• digoxin
• chronic digoxin toxicity
• emergency department
• elderly patient

Supporting Institution

None

Project Number

196

Ethical Statement

The study protocol was approved by the Mersin University Clinical Research Ethics Committee

Thanks

None

References

1. 1. Ziff OJ, Kotecha D. Digoxin: the good and the bad. Trends Cardiovasc Med. 2016;26(7):585-595.
2. 2. Joglar JA, Chung MK, Armbruster AL et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156.
3. 3. McDonagh TA, Metra M, Adamo M et al. 2023 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44:3627-3739.
4. 4. Kapelios CJ, Lund LH, Benson L et al. Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry. Eur Heart J Cardiovasc Pharmacother. 2022;8(8):756-767.
5. 5. Qamer SZ, Malik A, Bayoumi E et al. Digoxin use and outcomes in patients with heart failure with reduced ejection fraction. Am J Med. 2019;132(11):1311-1319.
6. 6. Kanji S, MacLean RD. Cardiac glycoside toxicity: more than 200 years and counting. Crit Care Clin. 2012;28(4):527-535.
7. 7. Biteker M, Başaran Ö, Dogan V et al. Real-life use of digoxin in patients with non-valvular atrial fibrillation: data from the RAMSES study. J Clin Pharm Ther. 2016;41(6):711-717.
8. 8. Luca SA, Faur-Grigori AA, Văcărescu C et al. Reconsidering digoxin in atrial fibrillation: from historical controversy to physiologically guided and personalized rate control. Biomedicines. 2025;13(12):3098.

9. 9. Regina AC, Rehman R, Hai O. Cardiac glycoside and digoxin toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 2025 Mar 25. PMID: 29083729.
10. 10. Wang X, Luo Y, Xu D et al. Effect of digoxin therapy on mortality in patients with atrial fibrillation: an updated meta-analysis. Front Cardiovasc Med. 2021;8:731135.
11. 11. Christensen LD, Reilev M, Juul-Larsen HG et al. Use of prescription drugs in the older adult population: a nationwide pharmacoepidemiological study. Eur J Clin Pharmacol. 2019;75(8):1125-1133.
12. 12. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6-14.
13. 13. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;36(28):1831-1838.
14. 14.Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347(18):1403-1411.
15. 15.Adams KF Jr, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group trial. J Am Coll Cardiol. 2005;46(3):497-504.
16. 16. Sonnenblick M, Abraham AS, Meshulam Z et al. Clinical and biochemical manifestations of digoxin toxicity. Br Med J (Clin Res Ed). 1983;286(6382):1975.